Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer

BACKGROUND: The ML18174 study, which showed benefits of bevacizumab (BEV) continuation beyond progression (BBP) for metastatic colorectal cancer (mCRC), excluded patients with first-line progression-free survival (PFS) shorter than 3 months. The present study was conducted to evaluate the efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Shun, Nagashima, Kengo, Kawakami, Takeshi, Mitani, Seiichiro, Komoda, Masato, Tsuji, Yasushi, Izawa, Naoki, Kawakami, Kentaro, Yamamoto, Yoshiyuki, Makiyama, Akitaka, Yamazaki, Kentaro, Masuishi, Toshiki, Esaki, Taito, Nakajima, Takako Eguchi, Okuda, Hiroyuki, Moriwaki, Toshikazu, Boku, Narikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555183/
https://www.ncbi.nlm.nih.gov/pubmed/34715820
http://dx.doi.org/10.1186/s12885-021-08890-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555183/
https://www.ncbi.nlm.nih.gov/pubmed/34715820
http://dx.doi.org/10.1186/s12885-021-08890-6

Ejemplares similares